Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator and beta-adrenergic agonist. Its exact mechanism in peripheral vascular disease is not fully understood but may involve direct relaxation of vascular smooth muscle and possibly smooth muscle in the gastrointestinal tract.
## Primary Indications
* Treatment of peripheral vascular disease, including intermittent claudication and Raynaud's disease. (Note: Efficacy is debated and not widely supported by current evidence).
## Adult Dosing
* **Oral:** The typical dose is 10-20 mg by mouth 3 to 4 times daily.
* **Maximum Dose:** Not well established, but doses exceeding 20 mg per administration are generally not recommended.
## Pediatric Dosing
* Information on pediatric dosing is not established or readily available. Use in pediatric patients is generally not recommended.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, but caution may be warranted in severe cases due to potential for altered metabolism and excretion.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Do not administer intravenously.
* Avoid use in patients with recent arterial bleeding or in the presence of glaucoma.
* Caution in patients with cardiac arrhythmias.
## Adverse Effects
* **Common:** Nausea, vomiting, gastric distress, dizziness, weakness, flushing, nervousness, rash.
* **Less Common:** Hypotension, tachycardia, gastrointestinal cramping, headache, blurred vision.
## Key Drug Interactions
* **Antihypertensives:** May potentiate hypotensive effects.
* **Epinephrine:** Isoxsuprine may reduce the vasoconstrictor and pressor effects of epinephrine.
## Monitoring
* Monitor for therapeutic response (improvement in claudication, reduced symptoms of peripheral vascular disease).
* Monitor for adverse effects, particularly hypotension, tachycardia, and gastrointestinal distress.
* Monitor blood pressure and heart rate.
## Clinical Pearls
* Isoxsuprine is generally considered to have limited efficacy in the treatment of peripheral vascular disease and is not a first-line agent. Its use should be carefully considered and weighed against evidence-based alternatives.
* Ensure patient education regarding potential side effects and the importance of reporting any adverse reactions.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical judgment. Always consult current prescribing information and relevant guidelines before making therapeutic decisions.
